[{"id":"e70949fa-f6da-468e-ba87-52cbfea4f3c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06478862","created_at":"2025-02-25T16:47:59.440Z","updated_at":"2025-02-25T16:47:59.440Z","phase":"Phase 2","brief_title":"Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy","source_id_and_acronym":"NCT06478862","lead_sponsor":"Lipomedix Pharmaceuticals Inc.","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Promitil (pegylated liposomal mitomycin-c prodrug)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2024","start_date":" 06/13/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-05"},{"id":"c3200199-23f9-4969-9bef-62b59f17d39f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01705002","created_at":"2021-01-18T07:25:16.922Z","updated_at":"2024-07-02T16:37:09.097Z","phase":"Phase 1","brief_title":"Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.","source_id_and_acronym":"NCT01705002","lead_sponsor":"Lipomedix Pharmaceuticals Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • capecitabine • Promitil (pegylated liposomal mitomycin-c prodrug)"],"overall_status":"Completed","enrollment":" Enrollment 88","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2018-07-10"}]